Back to Research Home
VRTXVertex Pharmaceuticals Inc
Health Care · Biotechnology · Large
$523.93−2.10%
As of 23 Oct 2026Mkt cap $141B
Stage 13
AVOID
Fundamentals
35.8/75
Technical
6.7/15
Independent
42.5/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +0.3%
- 3M
- +9.4%
- 6M
- +21.8%
- 1Y
- +22.9%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 30.5xHist median 28.2x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 35.6x
- FCF yield
- 2.8%
Quality
- ROIC
- 24.5%
- Operating margin
- 34.8%
- FCF margin
- 26.6%
- Current ratio
- 2.9x
Growth
- Revenue growth
- +8.9%Latest FY YoY
- Revenue CAGR
- +12.2%
- EPS CAGR
- +14.2%
- FCF CAGR
- +7.3%
Capital
- Share-count trend
- −0.5%3Y annualised
- Net cash
- $3.2B-0.9x OCF
Annual trend
- CAGR 2021–2025
- +12.2%
- Latest · 2025
- $12B
- YoY
- +8.9%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-02
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded